Greg Moeck

3.8k citations

78 papers · 2.7k indexed · 1 hit paper · h-index 27

Impact in

Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 1%

Papers in

Molecular Medicine 33
- Antibiotic Resistance in Bacteria 33
Applied Microbiology and Biotechnology 8
- Antibiotic Use and Resistance 8

Co-authors: James W. Coulton Francis F. Arhin Adam Belley Thomas Parr Geoffrey A. McKay Ingrid Sarmiento Lucienne Letellìer Sylvain Beaulieu
Journals: Antimicrobial Agents and Chemotherapy (26 papers)Open Forum Infectious Diseases (9 papers)International Journal of Antimicrobial Agents (8 papers)Journal of Bacteriology (5 papers)Diagnostic Microbiology and Infectious Disease (5 papers)
Partner nations: United States Canada France

In The Last Decade

Greg Moeck

74 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Cefepime–Taniborbactam in Complicated Urinary Tract Infection 2024 · 67 citations

Peers

Countries citing papers authored by Greg Moeck

Since Specialization

Citations

This map shows the geographic impact of Greg Moeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Moeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Moeck more than expected).

Fields of papers citing papers by Greg Moeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Moeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Moeck. The network helps show where Greg Moeck may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Greg Moeck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Greg Moeck Line = papers co-authored together Greg Moeck links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection Antimicrobial Agents and Chemotherapy ·Greg Moeck, Leanne B. Gasink, Rodrigo E. Mendes, Leah N. Woosley, James Jollen Lumintang, Hongzi Chen, Florian Wagenlehner, Tim Henkel, Paul C. McGovern	2024	10
2	ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten Antimicrobial Agents and Chemotherapy ·Michael R. Jacobs, Caryn E. Good, Ayman M. Abdelhamed, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall, Andrea M. Hujer, Dillon F. Rudman, Robin Patel, David van Duin, Vance G. Fowler, Daniel D. Rhoads, David A. Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M. Papp‐Wallace, Robert A. Bonomo	2024	0
3	ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime Antimicrobial Agents and Chemotherapy ·Michael R. Jacobs, Ayman M. Abdelhamed, Caryn E. Good, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall, Andrea M. Hujer, Kristine M. Hujer, Robin Patel, David van Duin, Vance G. Fowler, Daniel D. Rhoads, David A. Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M. Papp‐Wallace, Robert A. Bonomo	2024	6
4	Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22 Journal of Antimicrobial Chemotherapy ·James A. Karlowsky, Mark G. Wise, Meredith Hackel, David A. Six, Tsuyoshi Uehara, Denis M. Daigle, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm	2024	12
5	2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI) Open Forum Infectious Diseases ·Marcus Dörr, Leanne B. Gasink, Tim Henkel, Greg Moeck, Д.А. Моисеенко, Scott A. McConnell, Paul C. McGovern	2023	1
6	2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study Open Forum Infectious Diseases ·Greg Moeck, Leanne B. Gasink, Marcus Dörr, Hongzi Chen, Leah N. Woosley, Rodrigo E. Mendes, Florian Wagenlehner, Tim Henkel, Paul C. McGovern	2023	2
7	Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes Journal of Medicinal Chemistry ·Robert E. Lee Trout, Allison L. Zulli, Eugen F. Mesaros, Randy W. Jackson, Steven A. Boyd, Bin Liu, Paula M. McMahon, Denis M. Daigle, W. Schmitz‐Dumont, ThongamNabakumarSINGH, 斎藤福見, Christopher Hugh Maycock, Jason Weiss, Mark Pulse, Daniel C. Pevear, Greg Moeck, L Xerri, Christopher J. Burns	2021	30
8	Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection Antimicrobial Agents and Chemotherapy ·Adam Belley, Sesi AVS Devarakonda, Francis F. Arhin, Greg Moeck	2017	6
9	Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus International Journal of Antimicrobial Agents ·G. Ralph Corey, Francis F. Arhin, Matthew A. Wikler, Daniel F. Sahm, Barry N. Kreiswirth, José R. Mediavilla, Samantha Good, 孙彦泽, Hai Jiang, Greg Moeck, Heidi Kabler, Sinikka Green, William O’Riordan	2016	28
10	Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study Clinical Infectious Diseases ·G. Ralph Corey, Samantha Good, Hai Jiang, Greg Moeck, Matthew A. Wikler, Sinikka Green, Paul S. Manos, Thomas H. Philpott, Rajesh Singh, Yi-Zhu Zhou, 正彦中村, William O’Riordan	2014	169
11	Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections New England Journal of Medicine ·G. Ralph Corey, Heidi Kabler, Purvi Mehra, Sandeep K. Gupta, J. Scott Overcash, Ashwin Porwal, Philip Giordano, Christopher Lucasti, Antonio L. Pérez, Samantha Good, Hai Jiang, Greg Moeck, William O’Riordan	2014	226
12	Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus International Journal of Antimicrobial Agents ·Francis F. Arhin, Ingrid Sarmiento, Thomas Parr, Greg Moeck	2011	11
13	Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital International Journal of Antimicrobial Agents ·Pierre Vaudaux, Elzbieta Huggler, Francis F. Arhin, Greg Moeck, Adriana Renzoni, Daniel P. Lew	2009	4
14	Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium Journal of Antimicrobial Chemotherapy ·Geoffrey A. McKay, Sylvain Beaulieu, Francis F. Arhin, Adam Belley, Ingrid Sarmiento, Thomas Parr, Greg Moeck	2009	114
15	Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis ChemMedChem ·Cláudia Alexandra Colaço Lourenço VIEGAS, Evelyne Dietrich, E. Leiderman, Tom J. Houghton, H Dickinson, Magdalena Vasileva, Francis F. Arhin, Ingrid Sarmiento, Ibtihal Fadhil, Thomas Soeder, Rudy Firdaus Christopher Bernard Sirau, Dario Lehoux, Greg Moeck, Thomas Parr, Adel Rafai Far	2008	21
16	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis Bioorganic & Medicinal Chemistry ·Kelly S.E. Tanaka, Tom J. Houghton, Ting Kang, Evelyne Dietrich, Daniel Delorme, Sandra S. Ferreira, Laurence Caron, Jirroodnejad, Francis F. Arhin, Ingrid Sarmiento, Dario Lehoux, Ibtihal Fadhil, Thomas Soeder, Jing Liu, Rudy Firdaus Christopher Bernard Sirau, Д. М. Ітченко, Greg Moeck, Thomas Parr, Adel Rafai Far	2008	36
17	Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters Diagnostic Microbiology and Infectious Disease ·Francis F. Arhin, K. M. Tomfohrde, Deborah C. Draghi, Charles Z Mitchell, Thomas Parr, Daniel F. Sahm, Greg Moeck	2008	13
18	Antimicrobial drug discovery through bacteriophage genomics Nature Biotechnology ·Jing Liu, Mohammed Dehbi, Greg Moeck, Francis F. Arhin, Pascale Bauda, Dominique Bergeron, Mario Callejo, Vincent Ferretti, Chen Xiaowei, Tony Kwan, John S. McCarty, Ramakrishnan Srikumar, Dan Williams, Jinzi J. Wu, Philippe Gros, N. Düzgüneşν, Michael S. DuBow	2004	175
19	An 8-Å Projected Structure of FhuA, A “Ligand-Gated” Channel of the Escherichia coli Outer Membrane Journal of Structural Biology ·Olivier Lambert, Greg Moeck, Daniel Lévy, Laure Plançon, Lucienne Letellìer, Jean Louis Rigaud	1999	17
20	Cell Envelope Signaling in Escherichia coli Journal of Biological Chemistry ·Greg Moeck, James W. Coulton, Kathleen Postle	1997	84

About Greg Moeck

Greg Moeck is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Clinical Biochemistry, Pharmacology and Infectious Diseases, having authored 78 papers that have together received 2.7k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (39 papers), Antimicrobial Resistance in Staphylococcus (34 papers), Antibiotic Resistance in Bacteria (33 papers), Bacterial Identification and Susceptibility Testing (16 papers), Bacterial Genetics and Biotechnology (12 papers), Antibiotic Use and Resistance (8 papers), Bacteriophages and microbial interactions (7 papers) and Pneumonia and Respiratory Infections (7 papers). The work is most often cited by research in Molecular Medicine (687 citations), Applied Microbiology and Biotechnology (153 citations), Clinical Biochemistry (458 citations), Infectious Diseases (1.1k citations) and Microbiology (318 citations). Greg Moeck has collaborated with scholars based in United States, Canada and France. Frequent co-authors include James W. Coulton, Francis F. Arhin, Adam Belley, Thomas Parr, Geoffrey A. McKay, Ingrid Sarmiento, Lucienne Letellìer, Sylvain Beaulieu, Daniel F. Sahm and Samantha Good. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Open Forum Infectious Diseases, International Journal of Antimicrobial Agents, Journal of Bacteriology and Diagnostic Microbiology and Infectious Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact